An interventional study of Metformin in Malignant Neoplasm of Thyroid Stage I and Malignant Neoplasm of Thyroid Stage II, sponsored by Mashhad University of Medical Sciences. Completed at 1 site in Iran, Islamic Republic of. Open to participants aged Up to 80 Years. Per ClinicalTrials.gov, last updated 2011-04-26.
Sponsored by Mashhad University of Medical Sciences · Not applicable, Interventional, and Treatment
Differentiated thyroid cancer is the most common neoplasm of endocrine system. After surgery and radioiodine treatment, thyroid stimulating hormone (TSH) suppression is the main goal which is achieved with levothyroxine treatment. Levothyroxine causes increased thyroid hormones which can have negative impact on bone and cardiovascular system. Anecdotal reports have shown that metformin can induce TSH suppression without change in T3 and T4 concentration. The purpose of this study was to prescribe metformin as additional drug to levothyroxin in order to decrease levothyroxine dosage.
9,365 studies on the registry are indexed under Neoplasms; 2,486 are open to participants now.
This study's enrollment of 51 is close to the median of 50 across 7,250 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Mashhad University of Medical Sciences is the lead sponsor of 90 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
patients who receive metformin in addition to levothyroxine
Drug: Metformin
patients who receive only levothyroxine
Drug: Metformin
in case group metformin is added to levothyroxine and levothyroxine is decreased by 30% .in control group levothyroxine is reduced by 30% and no metformin is added to the regimen.
TSH
Time frame: 3 months
freeT3,freeT4
Time frame: 3months
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mashhad University of Medical Sciences